TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9360001
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg reserpine plus 5 mg clopamide (R/C)
Study: 9360001
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalapril
Study: 29856470
Drug: Adrecizumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrecizumab (various doses)
Study: 26666481
Drug: High TEWL
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TEWL group (TEWL > 6.5 g/m(2)/h)
Study: 26666481
Drug: Daily emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emollient use in high TEWL group
Study: 15615797
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (no-PCI)
Study: 14969077
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg once a week
Study: 10382902
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human G‐CSF (rhG‐CSF)
Study: 8886213
Drug: Naprelan 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprelan 1,000 mg once daily
Study: 8886213
Drug: Naprelan 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprelan 1,000 mg once daily (open-label phase)
Study: 8886213
Drug: Naprosyn 500
Normalized name: Naprosyn 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprosyn 500 mg BID (open-label phase)
Study: 27317505
Drug: Classification-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-specific treatment (CS)
Study: 27317505
Drug: Non classification-specific
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non classification-specific treatment (NCs)
Study: 20025989
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three days a week for 6 months
Study: 12492726
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg single dose
Study: 12492726
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily for 7 days
Study: 9618124
Drug: Dietary fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fat restriction (22 g/day to 26 g/day)
Study: 7623005
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of hepatitis A antigen per dose)
Study: 14971532
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of Pueraria mirifica (Group A)
Study: 14971532
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of Pueraria mirifica (Group B)
Study: 14971532
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica (both doses)
Study: 9469523
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg orally)
Study: 2821080
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg twice daily, maximum dose = 40 mg/d)
Study: 2821080
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg twice daily, maximum dose = 400 mg/d)
Study: 29042000
Drug: NBR biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBR biofeedback plus topiramate 50 mg (b.i.d.)
Study: 29042000
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg (b.i.d.)
Study: 26178748
Drug: Nerve Growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve Growth Factor (NGF) injection into extensor carpi radialis brevis (ECRB) muscle
Study: 26178748
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into extensor carpi radialis brevis (ECRB) muscle
Study: 17991805
Drug: Replacement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement therapy for SCTD; specific dosage and duration not mentioned.
Study: 16259942
Drug: Habit reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit reversal therapy (HR)
Study: 11329490
Drug: 4-methylpyrazole (4-MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-methylpyrazole (4-MP) 10-15 mg/kg p.o.
Study: 7962671
Drug: Bisoprolol hemifumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol hemifumarate (5 to 40 mg)
Study: 2891536
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oxmetidine
Study: 2891536
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oxmetidine
Study: 8054436
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Toxoplasma gondii
Study: 31319637
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (12.5 mg, 2.5 mL)
Study: 24048551
Drug: BST‐CarGel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BST‐CarGel treatment (n = 41)
Study: 24048551
Drug: Microfracture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfracture treatment alone (n = 39)
Study: 21639636
Drug: Culturally Informed
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Informed and Flexible Family‐Based Treatment for Adolescents (CIFFTA)
Study: 21639636
Drug: Traditional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Family Therapy (TFT)
Study: 19736179
Drug: Self-treatment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment of exacerbations with an action plan including prednisolone (with or without antibiotics).
Study: 19736179
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no self-treatment training).
Study: 19736179
Drug: Self-treatment group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment group.
Study: 9282449
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (third group)
Study: 9282449
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (fourth group)
Study: 8380610
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg every 12 hours for 14 days)
Study: 28851099
Drug: 2-ml autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-ml autologous platelet-rich plasma (PRP) injection
Study: 28851099
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy without injection (Control)
Study: 18486923
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies targeting adhesion molecules
Study: 17699341
Drug: Satavaptan 25
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 25 mg
Study: 17699341
Drug: Satavaptan 50
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 50 mg
Study: 17699341
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with Satavaptan
Study: 12689734
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drugs (specific drugs and dosages not mentioned)
Study: 1546124
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg/day
Study: 8923574
Drug: Moclobemide 600
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 600 mg/day
Study: 8923574
Drug: Moclobemide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (all doses)
Study: 2986508
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (400 mg five times daily for 10 days)
Study: 12060512
Drug: Topical ALA-PDT
Normalized name: Ala-Cort Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ALA-PDT
Study: 2360741
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (10 mg/kg, n = 8)
Study: 2360741
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (30 mg/kg, n = 7)
Study: 23842536
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (1.5 microgram/kg)
Study: 19361362
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine therapy without antibiotics
Study: 19361362
Drug: Imipenem‐cilastatin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem‐cilastatin (0.5 g every eight hours for ten days)
Study: 11059520
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid therapy
Study: 11059520
Drug: Systemic glucocorticoid
Normalized name: Glucocorticoids, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic glucocorticoid therapy
Study: 1412754
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy with cyclosporine and prednisolone
Study: 1412754
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with cyclosporine, azathioprine, and prednisolone
Study: 1412754
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy with cyclosporine and prednisolone (subgroup with azathioprine)
Study: 30474791
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 ml saline solution)
Study: 28412755
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anesthesia (group P, n = 25)
Study: 21677059
Drug: 4% l-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% l-arabinose in sucrose beverages
Study: 21677059
Drug: Control (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0% l-arabinose in sucrose beverages)
Study: 16952809
Drug: Perineural space
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural space expansion with 10 mL dextrose 5% in water (D5W) flush before catheter placement
Study: 9444798
Drug: Non-specific support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific support therapy (control)
Study: 7942533
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg aspirin
Study: 7942533
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of aspirin (81, 162, 324 mg)
Study: 3203047
Drug: Inhaled ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ouabain (1 mg)
Study: 20058619
Drug: Control (non-metformin)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (non-metformin)
Study: 10917406
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (1 mg single dose)
Study: 10917406
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (1 mg/day for 6 weeks)
Study: 10917406
Drug: Desacetyl-alpha-MSH (equimolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desacetyl-alpha-MSH (equimolar doses)
Study: 3582518
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy (5 days oral administration)
Study: 12847070
Drug: Tenecteplase +
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenecteplase + Enoxaparin (30 mg IV bolus followed by 1 mg/kg SC BID for 7 days)
Study: 12847070
Drug: Tenecteplase +
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenecteplase + Unfractionated Heparin (UFH)
Study: 7793887
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily oral doses for at least 3 weeks
Study: 2338029
Drug: Intravenous S/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous S/A (1.0/2.0 g)
Study: 2338029
Drug: Intravenous S/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous S/A (0.5/1.0 g)
Study: 2338029
Drug: Intramuscular S/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular S/A (0.5/1.0 g)
Study: 380913
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg 3-times daily)
Study: 380913
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg 3-times daily)
Study: 27733180
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg) administered once daily for 12 weeks
Study: 25675797
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF) after regional anesthesia (n=49)
Study: 25675797
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF) after general anesthesia (n=48)
Study: 25675797
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral feeding (ROF) after regional anesthesia (n=47)
Study: 25675797
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral feeding (ROF) after general anesthesia (n=48)
Study: 18191416
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (monotherapy)
Study: 15679698
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 6 mg (suma-sc)
Study: 12091866
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) once per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Study: 12091866
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) 3 times per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Study: 9816048
Drug: Carboxyamido-triazole (CAI)
Normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboxyamido-triazole (CAI) liquid formulation at doses of 100, 125, and 150 mg/m2/day and 200 and 330 mg/m2 every other day
Study: 9816048
Drug: Carboxyamido-triazole (CAI)
Normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboxyamido-triazole (CAI) gelcap formulation at doses of 100 and 125 mg/m2/day and 200 mg/m2 every other day
Study: 1675316
Drug: Propranolol (20-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20-160 mg twice daily)
Study: 7449302
Drug: Propranolol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (average daily dose 240 mg)
Study: 18620344
Drug: Right lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right lateral position (RLP) after swallowing the capsule
Study: 11461943
Drug: L-NAME +
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME + Placebo (PL)
Study: 11461943
Drug: L-NAME +
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME + Losartan (LOS)
Study: 11461943
Drug: L-NAME +
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME + Indomethacin (IND)
Study: 11461943
Drug: L-NAME +
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME + Indomethacin + Losartan (IND + LOS)
Study: 7978092
Drug: Ethanol 0.9
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.9 g/kg
Study: 7978092
Drug: Control (Ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Ethanol 0.0 g/kg)
Study: 29175569
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (10 mg/kg loading dose, then 1 mg·kg‐1·hr‐1 throughout surgery)
Study: 26160625
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of perindopril (4 mg morning and 4 mg evening)
Study: 26160625
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of losartan (50 mg morning and 50 mg evening)
Study: 26160625
Drug: Once-daily evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily evening administration of perindopril (8 mg)
Study: 26160625
Drug: Once-daily evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily evening administration of losartan (100 mg)
Study: 23293945
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (generic formulation, 1,200,000 IU)
Study: 10683714
Drug: 1% solution
Normalized name: GUMSOL 5%-0.01% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% solution of Citrus limon and Cydonia oblongata
Study: 10683714
Drug: 3% solution
Normalized name: Proxacol 3% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% solution of Citrus limon and Cydonia oblongata
Study: 8973432
Drug: Solar treatment
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solar treatment (water left in full sunlight)
Study: 1317657
Drug: L (Group
Normalized name: Meningococcal (Groups A,B,C,Y and W-135) Polysaccharide Vaccine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (Group BII)
Study: 30871628
Drug: Rituximab (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (induction therapy)
Study: 24692301
Drug: Triple DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple DMARD therapy + IM glucocorticoids
Study: 24692301
Drug: Triple DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple DMARD therapy + oral glucocorticoids
Study: 24692301
Drug: HCQ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ treatment
Study: 22974280
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg once daily for 18 weeks
Study: 22974280
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 18 weeks, then glimepiride 1-4 mg once daily for 34 weeks
Study: 9394942
Drug: Naltrexone, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, 1.0 mg/kg, daily
Study: 199128
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of naloxone
Study: 29306609
Drug: MED2005 (0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED2005 (0.2% glyceryl trinitrate topical gel)
Study: 26439240
Drug: Clonidine 0.3
Normalized name: CLONIDINE 0.3MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.3 mg (oral single dose)
Study: 22534709
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg qd)
Study: 12540331
Drug: Daily hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hypertonic saline nasal irrigation for 6 months
Study: 9824407
Drug: Capsaicin spray
Normalized name: capsaicin Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin spray solution delivering 0.15 mg of capsaicin per nostril once every second or third day for a total of seven treatments.
Study: 8109551
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of benazepril
Study: 8109551
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of benazepril
Study: 2681393
Drug: Mebendazole 200
Normalized name: mebendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 200 mg
Study: 2681393
Drug: Pyrantel 10
Normalized name: pyrantel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel 10 mg/kg
Study: 25880822
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact for 60 minutes, twice a day for 7 days
Study: 21430518
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 ml/kg)
Study: 21430518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 ml/kg tidal volume)
Study: 15501201
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d of glucosamine (n = 101)
Study: 10831989
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microgram)
Study: 9180103
Drug: E6010 (0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6010 (0.22 mg/kg body weight intravenously over 2 min)
Study: 9180103
Drug: Native t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native t-PA (28.8 mg or 14.4 million IU, 10% over 1 to 2 min, remainder over 60 min)